Nuvalent NUVL Stock
Nuvalent Price Chart
Nuvalent NUVL Financial and Trading Overview
| Nuvalent stock price | 75.2 USD |
| Previous Close | 43.08 USD |
| Open | 42.92 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 800 |
| Day's Range | 42.74 - 45.25 USD |
| 52 Week Range | 9.45 - 45.25 USD |
| Volume | 314.92K USD |
| Avg. Volume | 280.1K USD |
| Market Cap | 2.54B USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.93 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 46.75 USD |
NUVL Valuation Measures
| Enterprise Value | 2B USD |
| Trailing P/E | N/A |
| Forward P/E | -16.071943 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 5.711364 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Nuvalent Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 345.90% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 45.25 USD |
| 52 Week Low | 9.45 USD |
| 50-Day Moving Average | 37.31 USD |
| 200-Day Moving Average | 29.55 USD |
NUVL Share Statistics
| Avg. Volume (3 month) | 280.1K USD |
| Avg. Daily Volume (10-Days) | 276.27K USD |
| Shares Outstanding | 51.39M |
| Float | 22.66M |
| Short Ratio | 14.68 |
| % Held by Insiders | 4.43% |
| % Held by Institutions | 104.37% |
| Shares Short | 3.89M |
| Short % of Float | 31.14% |
| Short % of Shares Outstanding | 6.83% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -16.70% |
| Return on Equity (ttm) | -25.10% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -89497000 USD |
| Diluted EPS (ttm) | -1.71 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 450.46M USD |
| Total Cash Per Share (mrq) | 7.93 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 26.808 |
| Book Value Per Share (mrq) | 7.823 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -75843000 USD |
| Levered Free Cash Flow (ttm) | -43347752 USD |
Profile of Nuvalent
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | One Broadway |
| ZIP | 02142 |
| Phone | 857 357 7000 |
| Website | https://www.nuvalent.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 70 |
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase ½ clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is ongoing IND-enabling studies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Q&A For Nuvalent Stock
What is a current NUVL stock price?
Nuvalent NUVL stock price today per share is 75.2 USD.
How to purchase Nuvalent stock?
You can buy NUVL shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Nuvalent?
The stock symbol or ticker of Nuvalent is NUVL.
Which industry does the Nuvalent company belong to?
The Nuvalent industry is Biotechnology.
How many shares does Nuvalent have in circulation?
The max supply of Nuvalent shares is 72.09M.
What is Nuvalent Price to Earnings Ratio (PE Ratio)?
Nuvalent PE Ratio is now.
What was Nuvalent earnings per share over the trailing 12 months (TTM)?
Nuvalent EPS is -3.93 USD over the trailing 12 months.
Which sector does the Nuvalent company belong to?
The Nuvalent sector is Healthcare.
Nuvalent NUVL included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17366.13 USD — |
-0.1
|
9.58B USD — | 17128.71 USD — | 17467.35 USD — | — - | 9.58B USD — |
| NASDAQ Biotechnology NBI | 4184.77 USD — |
+1.29
|
— — | 4144.83 USD — | 4202.15 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 931.02 USD — |
+0.81
|
— — | 921.75 USD — | 934.48 USD — | — - | — — |
| Nasdaq US 700 Small Cap Index NQUS700SC | 2076.39 USD — |
+0.55
|
— — | 2051.38 USD — | 2085.49 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4157.43 USD — |
+0.21
|
— — | 3927.42 USD — | 4157.43 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 8495.19 USD — |
-0.11
|
— — | 8378.66 USD — | 8543.96 USD — | — - | — — |
- {{ link.label }} {{link}}